This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Homatropine" – news · newspapers · books · scholar · JSTOR (October 2021) (Learn how and when to remove this message) |
| 👁 Image | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601006 |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.001.561 👁 Edit this at Wikidata |
| Chemical and physical data | |
| Formula | C16H21NO3 |
| Molar mass | 275.348 g·mol−1 |
| 3D model (JSmol) | |
| |
| 👁 ☒ N👁 check Y (what is this?) (verify) | |
Homatropine (Equipin, Isopto Homatropine) is an anticholinergic medication that is an antagonist at muscarinic acetylcholine receptors and thus the parasympathetic nervous system. It is used in eye drops as a cycloplegic (to temporarily paralyze accommodation), and as a mydriatic (to dilate the pupil).
The related chemical compound homatropine methylbromide (methylhomatropine) is a different medication. Homatropine is less potent than atropine and has a shorter duration of action. It is available as the hydrobromide salt. Homatropine is also given as an atropine substitute,[1] given to reverse the muscarinic and CNS effects associated with indirect cholinomimetic (anti-AChase) administration.
Homatropine hydrobromide is on the World Health Organization's List of Essential Medicines.[2]
It is an antagonist of all five muscarinic acetylcholine receptors.[3]
Side effects
[edit]- Blurred vision
- Sensitivity to light
Contraindications
[edit]- Untreated glaucoma
- Myasthenia gravis
- Severe heart failure
- Thyrotoxicosis
References
[edit]- ^ Scharer LL, Burhenne HJ (April 1964). "Megacolon associated with administration of an anticholinergic drug in a patient with ulcerative colitis". The American Journal of Digestive Diseases. 9 (4): 268–274. doi:10.1007/bf02232133. PMID 14142388. S2CID 19169565.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ^ Lavrador M, Cabral AC, Veríssimo MT, Fernandez-Llimos F, Figueiredo IV, Castel-Branco MM (January 2023). "A Universal Pharmacological-Based List of Drugs with Anticholinergic Activity". Pharmaceutics. 15 (1): 230. doi:10.3390/pharmaceutics15010230. PMC 9863833. PMID 36678858.
- CS1:Vancouver names with accept markup
- Articles with short description
- Short description is different from Wikidata
- Articles needing additional references from October 2021
- All articles needing additional references
- Drugs with non-standard legal status
- Articles with changed CASNo identifier
- Articles with changed DrugBank identifier
- Articles with changed EBI identifier
- ECHA InfoCard ID from Wikidata
- Articles without KEGG source
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- All stub articles
